Gaurav Aggarwal Bio

Dr. Aggarwal has been an investor in the life sciences sector for more than twenty years. He rejoined Vivo as a Managing Partner in April 2024 after being a Managing Director from 2016 to 2023 and Chief Investment Officer for the U.S. public investment fund from 2021 to 2023. Dr. Aggarwal previously served as the Chief Business Officer of Ocera Therapeutics, Inc., a publicly traded clinical stage company developing therapies for orphan liver conditions, from April 2014 through October 2016, and as Managing Director of Investor Growth Capital from January 2013 through December 2013. Additionally, he was a General Partner at Panorama Capital, L.P., a venture capital fund, from August 2006 through December 2012. Earlier in his career, Dr. Aggarwal was an associate with JPMorgan Partners, LLC, a private equity division of JPMorgan Chase & Co. Dr. Aggarwal has served on the boards of Unicycive Therapeutics and Geron since March 2023 and November 2023, respectively. He previously held positions on the boards of Sierra Oncology, Inc. (acquired by GlaxoSmithKline plc), Hyperion Therapeutics, Inc. (acquired by Horizon Pharma plc), and on several privately held biopharmaceutical companies. Dr. Aggarwal received his M.D. from Columbia University, College of Physicians & Surgeons and his B.S. in Agricultural Economics from Cornell University.